MCID: MCN001
MIFTS: 49

Mucinous Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Mucinous Adenocarcinoma

MalaCards integrated aliases for Mucinous Adenocarcinoma:

Name: Mucinous Adenocarcinoma 12 14 69
Mucin-Producing Adenocarcinoma 12 69
Pseudomyxoma Peritonei with Unknown Primary Site 12
Mucin-Secreting Adenocarcinoma 12
Mucin-Secreting Carcinoma 12
Adenocarcinoma, Mucinous 42
Mucous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3030
MeSH 42 D002288
SNOMED-CT 64 72495009 900006

Summaries for Mucinous Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which produce mucin.

MalaCards based summary : Mucinous Adenocarcinoma, also known as mucin-producing adenocarcinoma, is related to ovarian mucinous adenocarcinoma and bile duct mucinous adenocarcinoma. An important gene associated with Mucinous Adenocarcinoma is MUC2 (Mucin 2, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are MicroRNAs in cancer and Development ERBB-family signaling. The drugs Bevacizumab and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include colon, prostate and appendix, and related phenotypes are Decreased viability and endocrine/exocrine gland

Related Diseases for Mucinous Adenocarcinoma

Diseases related to Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 338)
id Related Disease Score Top Affiliating Genes
1 ovarian mucinous adenocarcinoma 33.8 KRT20 MUC1 MUC2
2 bile duct mucinous adenocarcinoma 33.6 CDX2 KRAS
3 situs inversus 30.5 MUC1 MUC2
4 villous adenoma 29.1 CDKN2A EGFR TP53
5 adenocarcinoma in situ 28.9 CDKN2A CDX2 KRAS TP53
6 gastrointestinal stromal tumor 28.5 CDKN2A EGFR TP53
7 sertoli-leydig cell tumor 27.3 CDKN2A EGFR KRAS MLH1 MUC1 TP53
8 gallbladder cancer 26.7 CDKN2A CDX2 EGFR KRAS MLH1 MUC2
9 colorectal cancer 25.9 CDKN2A CDX2 EGFR KRAS KRT20 MLH1
10 colon mucinous adenocarcinoma 12.0
11 endometrial mucinous adenocarcinoma 12.0
12 mucinous adenocarcinoma of the appendix 12.0
13 mucinous adenocarcinoma of ovary 12.0
14 cervical mucinous adenocarcinoma 11.9
15 ampulla of vater mucinous adenocarcinoma 11.8
16 uterine ligament mucinous adenocarcinoma 11.8
17 fallopian tube mucinous adenocarcinoma 11.8
18 rectum mucinous adenocarcinoma 11.8
19 signet ring cell variant cervical mucinous adenocarcinoma 11.8
20 villoglandular variant cervical mucinous adenocarcinoma 11.8
21 intestinal variant cervical mucinous adenocarcinoma 11.8
22 endocervical type cervical mucinous adenocarcinoma 11.8
23 appendix adenocarcinoma 11.6
24 pseudomyxoma peritonei 11.3
25 adenocarcinoma 10.9
26 anal colloid adenocarcinoma 10.8
27 mucinous stomach adenocarcinoma 10.8
28 urinary system disease 10.8 MUC1 MUC2
29 laryngeal neuroendocrine tumor 10.8 KRAS MUC1
30 mucoepidermoid esophageal carcinoma 10.8 MUC1 MUC2
31 ascending colon cancer 10.8 KRT20 MUC2
32 bestiality 10.8 MUC1 MUC2
33 gastric papillary adenocarcinoma 10.7 KRAS MUC1
34 periosteal osteogenic sarcoma 10.7 KRT20 NKX2-1
35 small intestine cancer, childhood 10.7 KRT20 NKX2-1
36 lice infestation 10.7 MLH1 MUC1
37 parachordoma 10.7 KRAS NKX2-1
38 bile duct clear cell adenocarcinoma 10.6 CDX2 MUC2
39 papilloma 10.6 MLH1 MUC1
40 bladder benign neoplasm 10.6 KRAS NKX2-1
41 vulva squamous cell carcinoma 10.6 CDKN2A KRT20
42 bladder colloid adenocarcinoma 10.6 CDKN2A MUC1
43 sensory system cancer 10.6 CDX2 KRT20
44 lung occult small cell carcinoma 10.6 CDX2 KRT20
45 fibroepithelial polyp of urethra 10.6 CDX2 KRT20
46 pulmonary type ovarian small cell carcinoma 10.6 CDKN2A MUC1
47 acinar cell cystadenocarcinoma 10.6 KRAS MUC1 MUC2
48 gastric adenocarcinoma 10.6 CDX2 KRT20
49 sphenoid sinus squamous cell carcinoma 10.6 KRT20 NKX2-1
50 diffuse meningeal melanocytosis 10.6 CDKN2A MUC1

Graphical network of the top 20 diseases related to Mucinous Adenocarcinoma:



Diseases related to Mucinous Adenocarcinoma

Symptoms & Phenotypes for Mucinous Adenocarcinoma

GenomeRNAi Phenotypes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.32 EGFR KRAS MUC1
2 Decreased viability GR00106-A-0 9.32 KRAS
3 Decreased viability GR00221-A-1 9.32 EGFR KRAS
4 Decreased viability GR00221-A-2 9.32 KRAS
5 Decreased viability GR00221-A-4 9.32 EGFR
6 Decreased viability GR00301-A 9.32 KRAS
7 Decreased viability GR00381-A-1 9.32 KRAS
8 Decreased cell migration GR00055-A-1 9.26 ALK EGFR KRAS MUC1

MGI Mouse Phenotypes related to Mucinous Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.09 ALK CDKN2A CDX2 EGFR KRAS MLH1
2 cellular MP:0005384 10.08 NKX2-1 TP53 CDKN2A CDX2 EGFR KRAS
3 digestive/alimentary MP:0005381 10.06 CDKN2A CDX2 EGFR KRAS MLH1 MUC2
4 homeostasis/metabolism MP:0005376 10.06 EGFR KRAS MLH1 MUC2 NKX2-1 TP53
5 neoplasm MP:0002006 10.02 ALK CDKN2A CDX2 EGFR KRAS MLH1
6 reproductive system MP:0005389 9.86 ALK CDKN2A CDX2 EGFR KRAS MLH1
7 pigmentation MP:0001186 9.72 ALK CDKN2A EGFR KRAS TP53
8 respiratory system MP:0005388 9.7 ALK CDKN2A EGFR KRAS MLH1 NKX2-1
9 skeleton MP:0005390 9.5 ALK CDKN2A CDX2 EGFR KRAS NKX2-1
10 vision/eye MP:0005391 9.1 ALK CDKN2A EGFR KRAS MLH1 TP53

Drugs & Therapeutics for Mucinous Adenocarcinoma

Drugs for Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 210)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
2
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
3
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
6
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
7
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
10
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
11
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
12
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
13
Topotecan Approved, Investigational Phase 2, Phase 3, Phase 1 119413-54-6, 123948-87-8 60700
14
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
15
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
16
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
17
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
18
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
19
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
20
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
21
Metformin Approved Phase 2, Phase 3,Phase 1 657-24-9 14219 4091
22
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
23
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
24
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
26
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
27
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
28
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
29
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
30
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
31
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
32
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
33 Alkylating Agents Phase 3,Phase 2,Phase 1
34 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
35 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
36 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
37 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
38 Antidotes Phase 3,Phase 2,Phase 1
39 Antimetabolites Phase 3,Phase 2,Phase 1
40 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
41 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
42 Calcium, Dietary Phase 3,Phase 2,Phase 1
43 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
44 Micronutrients Phase 3,Phase 2,Phase 1,Early Phase 1
45 Mitomycins Phase 3
46 Nucleic Acid Synthesis Inhibitors Phase 3
47 Protective Agents Phase 3,Phase 2,Phase 1
48 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
49 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
50 Trace Elements Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 179)

id Name Status NCT ID Phase Drugs
1 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
2 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
3 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
4 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
5 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
7 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
8 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
9 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
10 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
11 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
12 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
13 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
14 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
15 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
16 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
17 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
18 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
19 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
20 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
21 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
22 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
23 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
24 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
25 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
26 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
27 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
28 Comparison of Adjuvant Chemotherapy Regimens in Treating Patients With Stage II or Stage III Rectal Cancer Who Are Receiving Radiation Therapy and Fluorouracil Before or After Surgery Terminated NCT00068692 Phase 3 capecitabine;fluorouracil;leucovorin calcium;irinotecan hydrochloride;oxaliplatin
29 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
30 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
31 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
32 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
33 Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Unknown status NCT01079780 Phase 2 irinotecan hydrochloride
34 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
35 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
36 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
37 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
38 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
39 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
40 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
41 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
42 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
43 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
44 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
45 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
46 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
47 A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces Completed NCT00162110 Phase 2 cetuximab
48 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
49 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
50 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride

Search NIH Clinical Center for Mucinous Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, mucinous

Genetic Tests for Mucinous Adenocarcinoma

Anatomical Context for Mucinous Adenocarcinoma

MalaCards organs/tissues related to Mucinous Adenocarcinoma:

39
Colon, Prostate, Appendix, Liver, Ovary, Lung, Breast

Publications for Mucinous Adenocarcinoma

Articles related to Mucinous Adenocarcinoma:

(show top 50) (show all 564)
id Title Authors Year
1
Invasive mucinous adenocarcinoma with lepidic-predominant pattern coexisted with tuberculosis: a case report. ( 28687977 )
2017
2
Presentation of mucinous adenocarcinoma of renal pelvis masquerading as gross hydronephrosis: A histopathological surprise. ( 28702413 )
2017
3
Giant mucinous adenocarcinoma of the appendix: a case report. ( 28756772 )
2017
4
Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria. ( 27744658 )
2017
5
KRAS mutation-positive mucinous adenocarcinoma originating in the thymus. ( 28932588 )
2017
6
Metastatic Mucinous Adenocarcinoma and Carcinoid Tumor Arising From a Mature Cystic Teratoma of a Horseshoe Kidney. ( 28083486 )
2017
7
Prognosis of Signet Ring Cell Carcinoma of the Colon and Rectum and their Distinction of Mucinous Adenocarcinoma with Signet Ring Cells. A Comparative Study. ( 28785968 )
2017
8
The Importance of Appendectomy in Surgery for Mucinous Adenocarcinoma of the Ovary. ( 28060142 )
2017
9
Primary mucinous adenocarcinoma of the lung: A case report and review of the literature. ( 28927134 )
2017
10
Mucinous adenocarcinoma with lepidic pattern and with K-RAS mutation in a newborn with antenatal diagnosis of congenital pulmonary airway malformation. ( 28889407 )
2017
11
Mixed mucinous adenocarcinoma and somatostatinoma of the ampulla of Vater associated with neurofibromatosis type 1. ( 28693748 )
2017
12
Pulmonary Invasive Mucinous Adenocarcinoma and Mixed Invasive Mucinous/Non-Mucinous Adenocarcinoma- A Clinicopathological and Molecular Genetic Study with Survival Analysis. ( 28823574 )
2017
13
Mucinous adenocarcinoma in association with hidradenitis suppurativa. ( 28597923 )
2017
14
Endocrine Mucin-Producing Sweat Gland Carcinoma of the Eyelid Associated With Mucinous Adenocarcinoma. ( 28902090 )
2017
15
Primary mucinous adenocarcinoma of the vulva, intestinal type. ( 28791269 )
2017
16
Mucinous adenocarcinoma arising in an end ileostomy - a video vignette. ( 28677338 )
2017
17
Synchronous mucinous adenocarcinoma of the recto sigmoid revealed by and seeding an anal fistula. (A case report and review of the literature). ( 28641190 )
2017
18
Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. ( 28590015 )
2017
19
Agenesis of the dorsal pancreas associated with mucinous adenocarcinoma and cystic teratoma: a case report and literature review. ( 28174646 )
2017
20
Sonographic image of cervix epithelioid trophoblastic tumor coexisting with mucinous adenocarcinoma in a postmenopausal woman: A case report. ( 28930821 )
2017
21
Mucinous Adenocarcinoma of the Suprapubic Cystostomy Tract without Bladder Involvement. ( 28670674 )
2017
22
Vulvar Carcinosarcoma Composed of Intestinal-type Mucinous Adenocarcinoma Associated With Anaplastic Pleomorphic and Spindle Cell Carcinoma and Heterologous Chondrosarcomatous and Osteosarcomatous Elements: A Case Report and Review of the Literature. ( 28319579 )
2017
23
Mucinous adenocarcinoma on perianal fistula. A rising entity? ( 28929316 )
2017
24
Molecular characteristics of multifocal invasive mucinous adenocarcinoma of the lung: Report of a rare case. ( 28851076 )
2017
25
Urachal mucinous adenocarcinoma with pseudomyxoma peritonei: A case report. ( 28858081 )
2017
26
mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma. ( 27239184 )
2016
27
Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. ( 26774193 )
2016
28
Mucinous adenocarcinoma of the bladder: A case report and review of the literature. ( 27703678 )
2016
29
Conjunctival mucinous adenocarcinoma in an ostrich (Struthio camelus). ( 27362604 )
2016
30
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung. ( 26829311 )
2016
31
Intracystic papillary neoplasm with an associated mucinous adenocarcinoma arising in Rokitansky-Aschoff sinus of the gallbladder. ( 27316722 )
2016
32
Pseudomyxoma peritonei with intrathoracic extension: a rare disease with rarer presentation from low-grade mucinous adenocarcinoma of the appendix. ( 26729823 )
2016
33
ALK-rearranged adenocarcinoma with extensive mucin production can mimic mucinous adenocarcinoma: clinicopathological analysis and comprehensive histological comparison with KRAS-mutated mucinous adenocarcinoma. ( 27114375 )
2016
34
Primary mucinous adenocarcinoma of the vulva: A case report and review of the literature. ( 27073659 )
2016
35
Palliative Decompression of a Symptomatic Mucinous Adenocarcinoma of the Pancreas. ( 27694871 )
2016
36
Contrast-enhanced ultrasound improves accurate identification of appendiceal mucinous adenocarcinoma in an old patient: A case report. ( 27583883 )
2016
37
Primary Pulmonary Mucinous Adenocarcinoma Was Better Visualized on Delayed FDG PET/CT Imaging. ( 27454595 )
2016
38
Usefulness of (18)F-FDG PET/CT to Detect Metastatic Mucinous Adenocarcinoma Within an Inguinal Hernia. ( 26941865 )
2016
39
Vulvar mucinous adenocarcinoma with neuroendocrine differentiation: A case report and review of the literature. ( 26861721 )
2016
40
Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. ( 27626312 )
2016
41
Mucinous adenocarcinoma associated with chronic suppurative hidradenitis: Report of a case and review of the literature. ( 27424105 )
2016
42
Squamous esophageal carcinoma and mucinous adenocarcinoma of the colon - an unusual association. ( 27151719 )
2016
43
Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma. ( 27342421 )
2016
44
Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. ( 27987593 )
2016
45
Salivary mucinous adenocarcinoma of the mandible. ( 27167387 )
2016
46
Clinicopathologic and Prognostic Features in Patients with Peritoneal Metastasis from Mucinous Adenocarcinoma, Adenocarcinoma with Signet Ring Cells, and Adenocarcinoid of the Appendix Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy. ( 26597367 )
2016
47
Appendicular mucinous adenocarcinoma associated with pseudomyxoma peritonei, a rare and difficult imaging diagnosis. ( 27239665 )
2016
48
Magnetic resonance imaging findings and prognosis of gastric-type mucinous adenocarcinoma (minimal deviation adenocarcinoma or adenoma malignum) of the uterine corpus: Two case reports. ( 27123265 )
2016
49
Pulmonary Kirsten Rat Sarcoma Virus Mutation Positive Mucinous Adenocarcinoma Arising in aA Congenital Pulmonary AirwayA Malformation, Mixed Type 1 and 2. ( 27645976 )
2016
50
Mucinous adenocarcinoma arising from a residual supratentorial neurenteric cyst and expressing mutated KRAS: a case report. ( 27569299 )
2016

Variations for Mucinous Adenocarcinoma

Expression for Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Mucinous Adenocarcinoma.

Pathways for Mucinous Adenocarcinoma

Pathways related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1 12.27 CDKN2A EGFR KRAS TP53
2
Show member pathways
12.26 EGFR KRAS MUC1 TP53
3 12.25 CDKN2A EGFR KRAS MLH1 TP53
4
Show member pathways
12.24 ALK CDKN2A EGFR KRAS MLH1 TP53
5 11.94 EGFR KRAS TP53
6 11.84 EGFR KRAS MLH1 TP53
7 11.83 EGFR MLH1 TP53
8
Show member pathways
11.82 EGFR KRAS TP53
9 11.82 EGFR KRAS TP53
10 11.75 CDKN2A KRAS TP53
11 11.59 CDKN2A KRAS MLH1 TP53
12 11.52 CDKN2A MLH1 TP53
13 11.42 EGFR KRAS TP53
14 11.3 CDKN2A EGFR KRAS TP53
15 11.25 CDKN2A EGFR TP53
16 10.91 CDKN2A TP53
17
Show member pathways
10.9 CDKN2A TP53
18 10.79 CDKN2A EGFR KRAS TP53

GO Terms for Mucinous Adenocarcinoma

Biological processes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.63 KRAS MUC1 MUC2
2 positive regulation of gene expression GO:0010628 9.54 KRAS NKX2-1 TP53
3 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 MUC1 TP53
4 epithelial tube branching involved in lung morphogenesis GO:0060441 9.4 KRAS NKX2-1
5 positive regulation of transcription, DNA-templated GO:0045893 9.35 CDKN2A CDX2 EGFR NKX2-1 TP53
6 replicative senescence GO:0090399 9.32 CDKN2A TP53
7 cerebral cortex cell migration GO:0021795 9.26 EGFR NKX2-1
8 positive regulation of cellular senescence GO:2000774 9.16 CDKN2A KRAS
9 Ras protein signal transduction GO:0007265 8.8 CDKN2A KRAS TP53

Sources for Mucinous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....